Daniel G. Welch

Professional at Intercept Pharmaceuticals, Inc.

Daniel G. Welch

Daniel G. Welch

Professional at Intercept Pharmaceuticals, Inc.

Overview
Career Highlights

Sanofi-Synthelabo, Inc.
InterMune, Inc.
Triangle Pharmaceuticals, Inc.

RelSci Relationships

1442

Number of Boards

10

Birthday

1958

Age

61

Relationships
RelSci Relationships are individuals Daniel G. Welch likely has professional access to. A relationship does not necessarily indicate a personal connection.

Founder at Samsara Biocapital LLC

Relationship likelihood: Strong

President at Sofinnova Ventures, Inc.

Relationship likelihood: Strong

Co-Founder at Seattle Genetics, Inc.

Relationship likelihood: Strong

Executive Partner, Private Equity at Sofinnova Ventures, Inc.

Relationship likelihood: Strong

Co-Founder at Intercept Pharmaceuticals, Inc.

Relationship likelihood: Strong

President at Aptalis Pharma US, Inc.

Relationship likelihood: Strong

Consultant at Aerie Pharmaceuticals, Inc.

Relationship likelihood: Strong

Executive Partner, Private Equity at Sofinnova Ventures, Inc.

Relationship likelihood: Strong

Former Senior Vice President, Corporate Strategy & Business Development at AMAG Pharmaceuticals, Inc.

Relationship likelihood: Strong

Founder, President & Chief Executive Officer at Ultragenyx Pharmaceutical, Inc.

Relationship likelihood: Strong

Paths to Daniel G. Welch
Potential Connections via
Relationship Science
You
Daniel G. Welch
Professional at Intercept Pharmaceuticals, Inc.
Education
M.B.A.

Established in 1919 as the Department of Commerce of UNC Chapel Hill's College of Arts, the School was renamed the Kenan-Flagler Business School in 1991 to honor two prominent American business families and benefactors of the School: philanthropist Mary Lily Kenan Flagler and her husband, Henry Morrison Flagler. The renaming was in recognition of a generous gift from Frank Hawkins Kenan, another Kenan family member and benefactor of the School's Kenan Institute of Private Enterprise.

B.S.

A private research university with more than 15,000 students from around the world, the University of Miami is a vibrant and diverse academic community focused on teaching and learning, the discovery of new knowledge, and service to the South Florida region and beyond. Led by President Donna E. Shalala, the University comprises 12 schools and colleges serving undergraduate and graduate students in more than 180 majors and programs. In 2012, U.S.News & World Report ranked UM No. 44 in its “Best Colleges” listings, the fourth year in a row it has been among the top 50, and it continued to be the highest ranked school in Florida. U.S. News also cited several of its programs in “America’s Best Graduate Schools.” Established in 1925 during the region’s famous real estate boom, UM is a major research university engaged in $360 million in research and sponsored program expenditures a year. While the majority of this work is housed at the Miller School of Medicine, investigators conduct dozens of studies in other areas, including marine science, engineering, education, and psychology

MBA Unknown

The University of North Carolina at Chapel Hill also known as UNC, UNC-Chapel Hill, Chapel Hill, North Carolina, or simply Carolina is a coeducational public research university located in Chapel Hill, North Carolina, United States. North Carolina has been consistently ranked among the highest ranked universities in the United States and is one of the original eight Public Ivy schools that provide an Ivy League experience for a public schooling price. After being chartered in 1789, the university first began enrolling students in 1795, which allows it to be one of three schools to claim the title of the oldest public university in the United States.

Career History
Professional
Current

Seattle Genetics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing monoclonal antibody-based therapies for the treatment of cancer and autoimmune diseases. Its lead product, SGN-35, is in pivotal trial for patients with relapsed or refractory hodgkin lymphoma. The company's other product candidates in various stages of clinical trials include dacetuzumab (SGN-40), a humanized anti-CD40 antibody; lintuzumab (SGN-33), a humanized anti-CD33 antibody; SGN-70, a humanized anti-CD70 antibody for the treatment of autoimmune diseases; SGN-75, which is in Phase I clinical trials for metastatic renal cell carcinoma and non-Hodgkin lymphoma; ASG-5ME, a preclinical antibody-drug conjugate product candidate for the treatment of solid tumors; and SGN-19A, a preclinical antibody-drug conjugate product candidate for the treatment of hematologic malignancies. It has collaborations with Bayer Pharmaceuticals Corporation; Celldex Therapeutics, Inc.; Daiichi Sankyo Co., Ltd.; Genentech; GlaxoSmithKline LLC; MedImmune, Inc.; Millennium; PSMA Development Company LLC; and Genmab A/S. The company also has an antibody-drug conjugates co-development agreement with Agensys, Inc. The company was founded in 1998 and is headquartered in Bothell, Washington.

Professional
Current

Intercept Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline is OCALIVA which is used for the treatment of primary biliary cholangitis, nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia. The company was founded by Mark E. Pruzanski and Roberto Pellicciari on September 4, 2002 and is headquartered in New York, NY.

Executive Partner, Private Equity
2015 - Prior

Sofinnova is a clinical-stage biopharmaceutical venture capital firm focused on life science and information technology. They specializes in clinical and late preclinical investments in biopharmaceutical products and partner with entrepreneurs across all stages of company formation including securing initial funding, building successful management teams, forming impactful corporate alliances, and navigating the M&A acquisition or IPOs' process. Sofinnova invests in companies in the US and Europe that do business in the US, Israel, India, China, Japan and Europe.

Boards & Committees
Chairman, Compensation Committee
2007 - 2014

Corium International, Inc. is a commercial stage biopharmaceutical company, which develops, manufactures and commercializes pharmaceutical products. The company development platforms enable transdermal delivery of large molecules or biologics, including vaccines, peptides and proteins, as well as small molecules that are otherwise difficult to deliver in a transdermal dosage form. The firm offers its products under the brands Corplex and MicroCor. Corium International was founded by Gary W. Cleary and Adrian L. Faasse, Jr. in 1999 and is headquartered in Menlo Park, CA.

Transactions
Details Hidden

Valeant Pharmaceuticals International Corp. purchases InterMune, Inc. /Infergen Hepatities C Treatment Ops from InterMune, Inc.

Investments
Details Hidden

Corium International, Inc. is a commercial stage biopharmaceutical company, which develops, manufactures and commercializes pharmaceutical products. The company development platforms enable transdermal delivery of large molecules or biologics, including vaccines, peptides and proteins, as well as small molecules that are otherwise difficult to deliver in a transdermal dosage form. The firm offers its products under the brands Corplex and MicroCor. Corium International was founded by Gary W. Cleary and Adrian L. Faasse, Jr. in 1999 and is headquartered in Menlo Park, CA.

Public Holdings
Restricted data only for RelSci Professional users.
This web site is not endorsed by, directly affiliated with, maintained, authorized, or sponsored by Daniel G. Welch. The use of any trade name or trademark is for identification and reference purposes only and does not imply any association with the trademark holder. The Presence of Daniel G. Welch's profile does not indicate a business or promotional relationship of any kind between RelSci and Daniel G. Welch.